Printer Friendly

Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations.

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced the signature of a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-month formulation, a gonadotropin releasing hormone (GnRH) agonist analogue, effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible reduction of testosterone to castrate serum levels. Debiopharm has developed and received marketing authorisations for Salvacyl / Moapar in nine major European countries, including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.

"There is a genuine unmet medical and social need for the treatment of sexual deviations. Not many pharma companies are willing or courageous enough to provide this type of treatment but we feel that we have a responsibility to help doctors and patients with the tools they need, even if it is difficult or controversial," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

About Salvacyl(R)/Moapar(R)

In the treatment of sexual deviations in men, administration of Salvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms or intra-muscular weekly injections required with antiandrogens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there are fewer side effects.

Two studies have shown that regular injections of the active ingredient, triptorelin, over a period of eight months to seven years in male patients with sexual deviations demonstrated a good efficacy and safety profile. Triptorelin produced reversible serum castrate testosterone levels (defined as less than or equal to 1.735 nmol/L) in all patients, and concurrently with the decrease in testosterone levels, triptorelin treatment reduced deviant sexual behaviours in 35/36 patients with severe sexual deviations.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com/.
 Debiopharm S.A. Contacts

 Kim Bill
 VP, Corporate Development
 Tel.: +41(0)21-321-01-11
 Fax: +41(0)21-321-01-69
 kbill@debiopharm.com

 Additional Media Contacts

 In London

 Maitland
 Brian Hudspith
 Tel: +44(0)20-7379-5151
 bhudspith@maitland.co.uk

 In New York

 Russo Partners, LLC
 Wendy Lau
 Tel: +1-212-845-4272
 Fax: +1-212-845-4260
 wendy.lau@russopartnersllc.com



CONTACT: Debiopharm S.A. Contacts: Kim Bill, VP, Corporate Development, Tel.: +41(0)21-321-01-11, Fax: +41(0)21-321-01-69, kbill@debiopharm.com; Additional Media Contacts: In London, Maitland, Brian Hudspith, Tel: +44(0)20-7379-5151, bhudspith@maitland.co.uk; In New York, Russo Partners, LLC, Wendy Lau, Tel: +1-212-845-4272, Fax: +1-212-845-4260, wendy.lau@russopartnersllc.com
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 15, 2008
Words:504
Previous Article:Survey Reveals Most Americans Planning Vacations Within the U.S.; Tummy Troubles Top Travel Health Woes.
Next Article:After Effects: Giving Back Is Good for You.


Related Articles
Moapar(R) 3 Months Approved for the Lowering of Testosterone to Castrate Serum Levels for Control of Sexual Drive in Adult Men.
Debiopharm Signs International License Agreements for Sanvar(R).
Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer.
Debiopharm and Airmid Sign Option and License Agreement for the Development of Debio 0824, an ShK Peptide for Autoimmune Disorders.
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients.
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries.
Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters